RE:RE:RE:RE:DD list for BobbyMil_Man54 wrote: So essentially @ 2.7% the instuitutional holding is insignificant and Bobby was lying.....but that's what pumpers do.....wouldn't you agree Rosenberg?.....
DavidRosenberg wrote: Mil_Man54 wrote: Walter333 wrote: The failure of the world's largest hydro grow op, 201:1 RS, Constant dilution by any and all forms of management since inception, Shelving of micro PEA and scrapping of trials, World class extractions the CEOs other company failing at extractions and turning into a delivery company. I'm sure there's more, if anyone would like to add to the list for Bobby please feel free to do so.
Sure I'll jump on.....lied to investors to include in person to their faces regarding the issuing of the sales license when they were aware the samples had failed Health Canada Inspection.....voted to pay their salaries a year in advance......recently awarded themselves stock options for no performance.....new CEO, Anthony Durkacz, hired 6 marketing firms at a cost of $2.5M annually despite there being nothing to promote or market.....the RS was guaranteed to occur only with institutional investment backing but that was a lie......anyone else?.....
Alliance Growht partners were the investment bank that backed them up but it was used to raise money and dilute shares under raza's leadership at the time...
seperate to that
There is institutional backing but not much
https://www.nasdaq.com/market-activity/stocks/huge/institutional-holdings
here is more better example of ins backing but thats not fsd
https://www.nasdaq.com/market-activity/stocks/cmps/institutional-holdings
In theory if you compare all psychedelic drug research companies then yes FSD is undervalued (and thats not a professional opinion) im just going by my retail investor brain
I want to see the stock go up and see more institutional investor back it up they already have all the analsts etc
The hard part is grabbing their attention to actually do the analyzing so FSD Pharma needs to push hard to grab their attention, if institutional investors liked FSD Pharma stock would have gone up already
if you think from an undervalued stance then in theory it is if you compare it to the bigger psychedelic companies.
They need to start IND and stuff for the 2 drug compounds that they have with lucid
until then it will be crickets because the analysts that work for institutional investors need to see substance first.
Anthony as ceo made the right few steps im not sure if 2,5 a year in promo will work, I think that they need to grab attention of more institutional investors so they can analyze their drug compound.
If you look at $ELYM FSD Pharma's PEA Competition they had Stiefel bank back them up.
Anyways i agree with milman and graham that coverage from ins investors right now is low and needs a HUGE revamp.
Cheers im very exhaused today ttyl thank you for being kind and not attacking me today
i think we all want the same thing at the end of the day , I am beggining to understand your stance and emotion towards AD and FSD for past performance however i have hopium this time will be different. Hopefully,..
cheers